Certificates / SDS Search
    ContactUsLinkComponent
    mAbs-formulation-1920x760.png

    Key drivers to overcome obstacles in mAbs formulation and fill-finish

     Key drivers to overcome obstacles in mAbs formulation and fill-finish | Avantor

    The final critical steps in commercial monoclonal antibody (mAb) manufacturing — from bulk drug substance collection through formulation to final sterile filtration and fill — present several ongoing challenges that demand meticulous attention to detail and a well-thought-out process. This article offers solutions for operational excellence to optimize efficiency, mitigate risk and speed up time to market.

    Read more

    Author

    JerryKeybl.png

    Jerry Keybl

    Senior Vice President of Biopharma Products and Strategy at Avantor

    Jerry Keybl serves as Avantor's Senior Vice President of Biopharma Products and Strategy. He is responsible for driving integrated product strategy and execution in the Biopharma Production business for both traditional and novel modalities. Previously, he held a number of product management, marketing and strategy roles at MilliporeSigma with a particular focus on cell and gene therapies. He also served as a Project Leader at the Boston Consulting Group (BCG). He holds a PhD from MIT in Chemical Engineering and two undergraduate degrees from the University of Pennsylvania in Chemical Engineering and Finance.